No results found for “”
No results found for filter “”
-
Blog articles 22.05.25
How public-private partnerships are optimising the research ecosystem
Clinical Trials: The Innovative Health Initiative is showing the power of collaboration as a catalyst for change in European research
Read Article -
Blog articles 21.05.25
Cross-border trials: ‘Not every patient is as lucky as me’
Patient story: travelling to Germany for a clinical trial offered Savo Pilipovic access to life-saving melanoma therapy. But his story is the exception,...
Read Article -
Blog articles 20.05.25
Clinical trials: Good for patients, good for Europe (Guest blog)
The EU Biotech Act is a unique opportunity to strengthen Europe’s clinical research ecosystem and regain global competitiveness in life sciences. We present...
Read Article -
Statements & press releases 14.05.25
Almost 100 new medicine approvals tracked; new data gives clearest picture yet of delays for patients ...
EFPIA also publishes first report aimed specifically as a catalyst for action to tackle inequalities faced by smaller countries.
Read Article -
Statements & press releases 08.05.25
EFPIA’s recommendations for the future EU Multiannual Financial Framework
The future MFF should support the life sciences research and innovation ecosystem, ensure the competitiveness of the EU regulatory system and foster the...
Read Article -
Statements & press releases 07.05.25
New data shows no shift in access to medicines for millions of Europeans
EFPIA says perennial state of medicines inequality requires rapid action from multiple partners to address numerous interlinked barriers and delays to...
Read Article -
Blog articles 28.04.25
Unmet medical needs in chronic cardiovascular diseases: Innovative approaches to therapeutic adherence...
A narrow definition of unmet medical need overlooks the potential of existing medicines to improve outcomes for patients
Read Article -
Statements & press releases 25.04.25
New research shows voucher system to drive R&D in antimicrobial resistance (AMR) is 45% less expensive...
Antimicrobial resistance (AMR) is one of the world’s most pressing health emergencies. Yet despite the urgent need, private investment in antimicrobial...
Read Article -
Statements & press releases 17.04.25
A Strategy for European Life Sciences
EFPIA welcomes the Commission initiative to develop a robust EU Life Sciences Strategy to strengthen Europe competitiveness and close the innovation gap...
Read Article -
Statements & press releases 08.04.25
Pharma CEOs alert President von der Leyen to risk of exodus to the US
CEOs of the research-based pharmaceutical industry issued a stark warning to President von der Leyen that unless Europe delivers rapid, radical policy...
Read Article -
Blog articles 08.04.25
The legitimate need of promotion in the pharmaceutical industry (Guest blog)
The pharmaceutical industry's raison d'être is the research and development of new medicines. These innovations are key in combatting disease, extending...
Read Article -
Blog articles 20.03.25
Unmet medical need: How patient perspectives drive meaningful innovation (Guest blog)
A restrictive definition of unmet need would limit researchers’ capacity to deliver what matters to patients.
Read Article
No results found for “”
No results found for filter “”
-
EFPIA News 17.03.25
Harnessing RWE to transform healthcare decision-making in Europe
EFPIA vision on the role and use of RWE in decision-making
Read Article -
EFPIA News 29.01.25
Medicine shortages: EFPIA proposal for action
Together, all stakeholders share a responsibility and commitment to building resilient supply chains that ensure patients receive the medicines they need....
Read Article -
EFPIA News 24.01.25
EFPIA response to the adoption of the European Health Data Space (EHDS)
EFPIA welcomes the adoption of the European Health Data Space (EHDS) by the Council of the EU, marking a significant step forward in leveraging health...
Read Article -
EFPIA News 15.01.25
IMAGINE if Europe was a leader in life sciences
Just imagine if the EU Life Sciences Sector developed the next generation of therapies, attracted the best scientific research, developed the brightest...
Read Article -
EFPIA News 08.01.25
With NIRO navigate innovation and research opportunities
2025 has arrived, bringing a host of opportunities for R&I! Find which one(s) could best help you pursue groundbreaking work.
Read Article -
EFPIA News 18.11.24
Breaking barriers in Rare Disease Research: The Rare Disease Moonshot at two years
Rare diseases impact millions globally, yet fewer than 5% of the over 7,000 identified have treatments, underscoring an urgent need for action. The Rare...
Read Article -
EFPIA News 26.09.24
EFPIA position on opt-out in the EHDS Regulation
EFPIA stresses the importance of avoiding fragmentation and bias, clarifying the scope of the opt-out by limiting it to personal data and creating a centralised...
Read Article -
EFPIA News 11.07.24
NIRO: Navigating innovation and research opportunities
A new tool to help navigate the complex world of health R&I funding programmes.
Read Article -
EFPIA News 08.07.24
Breaking down barriers: Making cross-border access to clinical trials a reality
Collaborative effort by EFGCP and EFPIA develops action plan to address participation barriers in Europe
Read Article -
EFPIA News 12.06.24
New data from EFPIA reveals multiple factors leading to unequal access to medicines for patients across...
"Whatever the reason, whatever the cause, we stand ready to play our part in reducing the time it takes for patients to access the medicines we discover,...
Read Article -
EFPIA News 04.06.24
Insights from EFPIA's Reliance Webinar
On the 19th of March EFPIA have hosted a joint industry webinar on Reliance, providing a platform for information and discussion on use of EMA assessment...
Read Article -
EFPIA News 26.04.24
Journal article - Evolving assessment pathways for precision oncology medicines to improve patient access:...
This study describes challenges in assessing PO and TA medicines, explores possible solutions, and provides actionable recommendations to facilitate an...
Read Article
No results found for “”
No results found for filter “”
-
Statements & press releases 14.05.25
Almost 100 new medicine approvals tracked; new data gives clearest picture yet of delays for patients ...
EFPIA also publishes first report aimed specifically as a catalyst for action to tackle inequalities faced by smaller countries.
Read Article -
Statements & press releases 08.05.25
EFPIA’s recommendations for the future EU Multiannual Financial Framework
The future MFF should support the life sciences research and innovation ecosystem, ensure the competitiveness of the EU regulatory system and foster the...
Read Article -
Statements & press releases 07.05.25
New data shows no shift in access to medicines for millions of Europeans
EFPIA says perennial state of medicines inequality requires rapid action from multiple partners to address numerous interlinked barriers and delays to...
Read Article -
Statements & press releases 25.04.25
New research shows voucher system to drive R&D in antimicrobial resistance (AMR) is 45% less expensive...
Antimicrobial resistance (AMR) is one of the world’s most pressing health emergencies. Yet despite the urgent need, private investment in antimicrobial...
Read Article -
Statements & press releases 17.04.25
A Strategy for European Life Sciences
EFPIA welcomes the Commission initiative to develop a robust EU Life Sciences Strategy to strengthen Europe competitiveness and close the innovation gap...
Read Article -
Statements & press releases 08.04.25
Pharma CEOs alert President von der Leyen to risk of exodus to the US
CEOs of the research-based pharmaceutical industry issued a stark warning to President von der Leyen that unless Europe delivers rapid, radical policy...
Read Article -
Statements & press releases 19.03.25
Cancer care 2025: an overview of cancer outcomes data across Europe
Cancer survival rates improve across Europe, but disparities between countries remain
Read Article -
Statements & press releases 11.03.25
EFPIA response to the Critical Medicines Act
EFPIA supports the European Commission’s ambition to strengthen Europe’s medicines supply chain through the Critical Medicines Act.
Read Article -
Statements & press releases 10.03.25
EFPIA begins legal proceedings in European court, to seek clarity on Urban Wastewater Treatment Directive...
EFPIA believes that the obligations that the Directive imposes on producers of medicines run counter to key principles of EU Treaties: polluter-pays, proportionality...
Read Article -
Statements & press releases 05.03.25
A Call for Effective Stakeholder Engagement and Capacity Building during the Implementation of the European...
39 representatives of the EU health community welcome the publication of the EHDS in the Official Journal of the EU. We take the opportunity to call on...
Read Article -
Statements & press releases 03.03.25
EFPIA seeks clarity on Urban Wastewater Treatment Directive in the European Courts
Europe needs environmental legislation that works, where all sectors are incentivised to sustainably reduce micro-pollutants and where the costs of treatment...
Read Article -
Statements & press releases 28.02.25
EFPIA response to the publication of the Critical Medicines Alliance Strategic Report
EFPIA supports the European Commission’s goal of strengthening pharmaceutical supply chains and boosting EU competitiveness.
Read Article
No results found for “”
No results found for filter “”
-
Blog articles 22.05.25
How public-private partnerships are optimising the research ecosystem
Clinical Trials: The Innovative Health Initiative is showing the power of collaboration as a catalyst for change in European research
Read Article -
Blog articles 21.05.25
Cross-border trials: ‘Not every patient is as lucky as me’
Patient story: travelling to Germany for a clinical trial offered Savo Pilipovic access to life-saving melanoma therapy. But his story is the exception,...
Read Article -
Blog articles 20.05.25
Clinical trials: Good for patients, good for Europe (Guest blog)
The EU Biotech Act is a unique opportunity to strengthen Europe’s clinical research ecosystem and regain global competitiveness in life sciences. We present...
Read Article -
Blog articles 28.04.25
Unmet medical needs in chronic cardiovascular diseases: Innovative approaches to therapeutic adherence...
A narrow definition of unmet medical need overlooks the potential of existing medicines to improve outcomes for patients
Read Article -
Blog articles 08.04.25
The legitimate need of promotion in the pharmaceutical industry (Guest blog)
The pharmaceutical industry's raison d'être is the research and development of new medicines. These innovations are key in combatting disease, extending...
Read Article -
Blog articles 20.03.25
Unmet medical need: How patient perspectives drive meaningful innovation (Guest blog)
A restrictive definition of unmet need would limit researchers’ capacity to deliver what matters to patients.
Read Article -
Blog articles 05.03.25
Cancer care 2030: from policy ambition to impact (Guest blog)
Why is it important to continue the Europe's Beating Cancer Plan?
Read Article -
Blog articles 04.03.25
World Obesity Day: a chronic disease demands urgent action (Guest blog)
Scientific understanding and clinical management of obesity have evolved, but attitudes, policies and societal narratives have not kept pace.
Read Article -
Blog articles 27.02.25
How the CARE Consortium took on COVID-19 and what comes next (Guest Blog)
CARE Consortium published its white paper, telling the story of its five year journey from a flying start in April 2020 to bowing out at the end of March...
Read Article -
Blog articles 18.02.25
Towards a Systematic Approach to Monitoring Late Effects of Cancer Treatment (Guest Blog)
On February 4, marking World Cancer Day, Slovenia hosted the 5th Strategic Conference "Living with Cancer – Challenges Faced by Cancer Patients and Monitoring...
Read Article -
Blog articles 03.02.25
United by Unique: a call for people-centred cancer care on World Cancer Day 2025 (Guest Blog)
Cancer is more than just a medical diagnosis; it is a deeply personal experience. Each person's journey with cancer is unique, shaped by their socioeconomic...
Read Article -
Blog articles 03.02.25
Unlocking cross-border clinical trials for patients in Europe
The public consultation for the EU-X-CT draft recommendations has been extended, you have until 31 March 2025 to share your feedback.
Read Article